Clinical implications of plasma ctDNA features and dynamics in gastric cancer treated with HER2-targeted therapies.

ABSTRACT:

Background

Gastric cancer (GC) is confronted with limited options for precision medicine. Human epidermal growth factor receptor 2 (HER2) is the principal druggable target of GC, yet proper biomarkers for response/resistance prediction remain unveiled.

Methods

From 40 GC patients received HER2-targeted therapy, a total of 327 peripheral blood plasma specimens was collected including baseline and treatment time points. Circulating tumor DNA (ctDNA) was extracted and sequenced with a target panel of 425 genes. Experimental validation of resistant mutations was carried out in NIH-3T3 cell line.

Results

Genomic features, including ERBB2 copy number variation (CNV), total copy number load, and tumor mutation burdens (TMBs), dynamically changed along with the treatment proc

SUBMITTER: Zhang C 

PROVIDER: S-EPMC7737756 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature